Diego Holanda retweeted
💊 Can DFS be used as a surrogate for OS in early-stage pancreatic cancer trials?
📈 In a meta-analysis of 29 RCTs (n=6777), DFS strongly correlated with OS (R=0.70 adjuvant | R=0.90 neoadjuvant).
📍 DFS may be a reliable surrogate endpoint for OS.
bmjoncology.bmj.com/content/…
Diego Holanda retweeted
Paper 2/2 of our pilot prediction model to determine survival probability on #immunotherapy I would like to highlight the potential importance of the HLA-A point mutations in a neoantigen-restricted scenario (TMB-low cohort) @MDAndersonNews @pmcancercentre doi.org/10.1093/oncolo/oyaf0…
Diego Holanda retweeted
Our paper on how we're uniting the cancer research and care communities in Canada to accelerate precision oncology is out in @Cancer_Cell!
Read it now 👇
Online Now: The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative dlvr.it/TJyBmZ
Diego Holanda retweeted
Online Now: The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative dlvr.it/TJyBmZ
Diego Holanda retweeted
📌Happy to share our perspective on uveal melanoma management, just out in @ESMO_Open
With this amazing team @mauriciofribei1 @IanHirsch3
🔗 esmoopen.com/article/S2059-7…
Diego Holanda retweeted
Happy to share our review on the complexity of the TME and perspectives on targeting approaches 🎯 Thank you for the strong team work @JIPOEditors @ANaingMD, @MDAndersonNews @CarlosTorradoMD & @pmcancercentre @cdiegoholanda @anacveneziani @MegidThais | doi.org/10.36401/JIPO-24-23
Diego Holanda retweeted
🎬 It’s a wrap on two fantastic days of #LMS discussions and science with international colleagues!
Thanks to @NLMSF for this yearly round table.
Thanks to @GladdyLab and Albiruni Razak and the Toronto group for hosting us! Thanks to all speakers and participants!
Diego Holanda retweeted
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline ascopubs.org/doi/10.1200/JCO…
All women with breast cancer < 65 should get genetic testing. devem fazer o teste genético! Hospital Sírio-Libanês: única instituição da América Latina convidada.
Diego Holanda retweeted
⏰ Countdown to #ESMO23 @myESMO! Meet us on Saturday and check out our work on survival predictors among TMB-low #cancer patients treated with #immunotherapy @GalanteLab @pafgalante @cdiegoholanda @AwniBeatriz @jardim_denis
Diego Holanda retweeted
Congrats my dear friend @HaradaGuilherme 👏🏻👏🏻👏🏻
You’re a brilliant medical oncologist and scientist‼️ ⭐️
In a Review now published online, Guilherme Harada, Soo-Ryum Yang, @emilianoCocco2 and @alexdrilon discuss some molecular subtypes of #lungcancer that, despite occurring in <5% of patients with this cancer type, affect a considerable number of individuals nature.com/articles/s41571-0…
Diego Holanda retweeted
At #GI23 @ASCO you can meet our fellow @souza_zenaides presenting the results from 🇧🇷 real-life data on GEP-NETS treated with #Lu177 including ❇️G3 GEP-NETS data ❇️clinical & nuclear predictive features
@FellowsHsl @hsiriolibanes
Diego Holanda retweeted
Thank you, @Cancers_MDPI Editorial Office, for sharing our work! @jardim_denis @cdiegoholanda @AwniBeatriz @GalanteLab @pafgalante @FellowsHsl @hsiriolibanes
✨Do specific somatic mutations can modulate response to #immunotherapy? Check out this pilot study revisiting solid tumors patients’ survival patterns according to their mutational profiles✨
📜Find the full paper here👉mdpi.com/2072-6694/14/21/543…
Diego Holanda retweeted
Our paper about the "Interplay between Tumor Mutational Burden and Mutational Profile" is out! Fantastic team @CamilaBragancaX @cdiegoholanda @AwniBeatriz Eduardo Campos, Joao P Alves @DerGuardia @jardim_denis @pafgalante
mdpi.com/1926244 #mdpicancers via @Cancers_MDPI
Diego Holanda retweeted
Second report of a marked response to crizotinib in a NSCLC harbouring SLC12A2-ROS1 oncogenic fusion. The first one was described by Rodriguez-Antolin and colleagues from @HGregorioM @alessi_joao @KatzArtur @luizagadotti @sacardo_karina @cdiegoholanda @hsiriolibanes
Diego Holanda retweeted
Just out! After 1y of work and one ASCO poster presentation, I’m happy to share our full paper on CV toxicity after ICIs @sciencedirect @ELS_Oncology @jardim_denis @KatzArtur @HaradaGuilherme @cdiegoholanda sciencedirect.com/science/ar…
Diego Holanda retweeted
CDK12 alterations confer an aggressive phenotype to PCa. Our paper describes successful cases treated with DNA damaging therapies and immunotherapies in CDK12-altered mCRPC, potentially stimulating future studies evaluating this combinations. 👇clinical-genitourinary-cance…
Diego Holanda retweeted
TMB & mutational landscape interplay on OS for solid tumors treated w/ ICIs. ✅ TERT & NOTCH3 = better outcomes ⛔️ CCND3, TIMM8B, CDKN2B, STK11 & TP53 negatively impact prognosis. #TranslationalOncology #ESMOImmuno21 Check it out ➡️ cattendee.abstractsonline.co…
Diego Holanda retweeted
Nesse novembro branco, confira e compartilhe o conteúdo educativo sobre #cancerdepulmao em linguagem acessível para pacientes ▶️ 2/3 youtu.be/J9xzE60ShgI via @YouTube | Educational content for 🇧🇷 patients in #LCAM #CancerAwareness @GilbertodeCas13 @GBOT_Alerta





































